Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Dynamics of Serial ctDNA as Predictors of Clinical Outcomes in Metastatic and Locally Advanced PDAC: A Systematic Review

  • By

  • Supriya Peshin

  • Ehab Takrori

  • Ibrahim Halil Sahin

  • Harrison Kim

  • Mark Rubinstein

  • Claire Verschragen

  • Zahra Hamedi

  • Shafia Rahman

  • August 12, 2026

Share

Clinical Scorecard: Correction: Dynamics of Serial ctDNA as Predictors of Clinical Outcomes in Metastatic and Locally Advanced PDAC: A Systematic Review

At a Glance

CategoryDetail
ConditionMetastatic and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Key MechanismsSerial ctDNA dynamics
Target PopulationPatients with metastatic and locally advanced PDAC
Care SettingOncology

Key Highlights

  • Correction regarding authorship affiliation
  • Focus on ctDNA as a predictor of clinical outcomes
  • Systematic review methodology

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with metastatic and locally advanced PDAC

          Not specified in the correction

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review

            • by Supriya Peshin, Ehab Takrori, Ibrahim Halil Sahin, Harrison Kim, Mark Rubinstein, Claire Verschragen, Zahra Hamedi, Shafia Rahman

            • August 12, 2026

            Related Content

            Commentary: Case Report: Giant atypical granular cell tumor of the median nerve

            Correction: Lipid profile-based prognostic nomograms for obstructive colorectal cancer: multi-cohort development and validation

            GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair